|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Minicircle DNA-Engineered CAR T Cells Suppressed Tumor Growth in Mice.
|
31582530 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SynNotch receptors induced ROR1 CAR expression selectively within the tumor, resulting in tumor regression without toxicity when tumor cells were segregated from, but not when co-localized with, normal ROR1<sup>+</sup> cells.
|
30889382 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future.
|
30721445 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have explored the benefits of incorporating the IL15 cytokine within the CAR cassette to provide both a survival signal before antigen encounter, and an additional cytokine signaling at the tumor site using a neuroblastoma tumor model.
|
30617136 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review we discuss some of the mechanistic contributions intrinsic to the CAR-T construct, the tumor being treated, and the individual patient that impact the development and severity of CRS and neurotoxicity.
|
31355491 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors <i>in vivo</i>.
|
30651858 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing.
|
31114587 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive T cell transfer therapy (ACT) using tumor infiltrating lymphocytes or lymphocytes redirected with antigen receptors (CAR or TCR) has revolutionized the field of cancer immunotherapy.
|
30842774 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In in vivo experiment, we confirmed how DOC enhanced the recruitment of HER2-CAR T cells to tumor sites.
|
30744691 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, their broad use is limited since a CAR targets a single tumor associated antigen (TAA), which is not effective against tumors with heterogeneous TAA expression or emerging antigen loss variants.
|
30984613 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, the CAR-T cells inhibited growth of cell-line- and patient-derived xenograft TNBC tumors in mice.
|
31804974 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells lacking all three NR4A transcription factors (Nr4a triple knockout) promoted tumour regression and prolonged the survival of tumour-bearing mice.
|
30814732 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The spectral characterisation and unmixing validation studies reported here established that iLH<sub>2</sub> is superior to LH<sub>2</sub> for the spectral unmixing of bioluminescent signals in vivo; which led to this novel near-infrared dual BLI system being applied to monitor both tumour burden and CAR T cell therapy within a systemically induced mouse tumour model.
|
31610848 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cell therapy has achieved unprecedented success among hematologic tumors, but its role in treating solid tumors is still unclear.
|
30886654 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection.
|
30649750 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Selective anti-tumor activity in the absence of toxicity provides proof-of-concept that micromolar affinity tuned CAR T cells can be used to target tumors expressing high levels of antigen while avoiding normal tissues expressing basal levels of the same antigen.
|
31337787 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.
|
30734529 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR is involved in the formation of epithelial tight junctions and promotes tumor growth in some cancers.
|
31512325 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Redirecting the recognition specificity of T lymphocytes to designated tumour cell surface antigens by transferring chimeric antigen receptor (CAR) genes is becoming an effective strategy to combat cancer.
|
31004624 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, lack of response to CAR T cell treatment is due in some cases to intrinsic autologous T cell defects and/or the inability of these cells to function optimally in a strongly immunosuppressive tumor microenvironment.
|
30735463 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this landscape, most studies have primarily focused on improving CAR-T cells and overcoming the unfavorable effects of tumor microenvironment on solid tumors.
|
31754328 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Some published studies have demonstrated that CAR-T could inhibit tumor growth and cause severe side effects.
|
30659408 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Given that multiple genetic alterations are the main factors that drive genesis and development of tumor, CRISPR-Cas9 system has been applied to correct cancer-causing gene mutations and deletions and to engineer immune cells, such as chimeric antigen receptor T (CAR T) cells, for cancer immunotherapeutic applications.
|
29579146 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While immunotherapy with chimeric antigen receptor T (CAR-T) cells has shown much promise in haematological malignancies, their efficacy for solid tumours is challenged by the lack of tumour-specific antigens required to avoid on-target, off-tumour effects.
|
30121627 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, our data suggested that AMG102 treatment alone might increase leukocyte infiltration including efficient CAR-T access into tumor mass and thereby improves its antitumor activity.
|
31621900 |
2019 |